Patients with nevoid basal cell carcinoma syndrome carry germline mutations in the tumor suppressor gene Patched 1 (PTCH1) and are predisposed to develop basal cell carcinoma (BCC), medulloblastoma (MB), and rhabdomyosarcoma (RMS). These tumors are also present in the murine model for Ptch1 deficiency, the Ptch1
Introduction
The Hedgehog (Hh) signaling pathway plays a fundamental role in development and tumorigenesis and determines cell fate in a variety of tissues, including brain, muscle and skin (1, 2) . The core components of this signaling pathway are the morphogen Sonic Hedgehog (Shh) and its receptor Patched 1 (Ptch1) that inhibits the transmembrane protein Smoothened (Smo). Binding of Shh to Ptch1 suspends its inhibiting function and leads to the activation of the Gli-Krüppel zinc finger transcription factors (3) . Constitutive activation of the Hh signaling pathway causes the formation of tumors including basal cell carcinoma (BCC), medulloblastoma (MB) and rhabdomyosarcoma (RMS) (4, 5) . Germline mutations in the PTCH1 gene have been found in patients with nevoid basal cell carcinoma syndrome (NBCCS) (6, 7) who are predisposed to BCC, MB, RMS and other tumors (8) . Additionally, somatic PTCH1 mutations have been detected in sporadic cases of BCC and MB (9, 10) . Notably, Ptch1-deficient mouse strains develop tumors comparable to those in humans with NBCCS including BCC, MB and RMS. These tumors consistently overexpress downstream targets of the activated Hh signaling pathway such as Gli1, Igf2 and Ptch1 itself (4, 5, 11) .
The forkhead box protein Foxf1 belongs to the superfamily of forkhead/winged-helix transcription factors that regulate cellular proliferation, differentiation and metabolic homeostasis (12) . Foxf1 expression begins at 6.5 days post coitum (13) and is essential for the development of gut derived organs, such as the esophagus, trachea, lung and intestine, as well as of the head and brain (13) (14) (15) (16) . As Foxf1 plays an important role during early development, Foxf1 knock out mice die in utero (17) . However, this transcription factor is also expressed during adulthood in the lung, liver, intestine and brain (13, 14, 16, 18, 19) . Notably, Foxf1 haploinsufficiency in the mouse results in the same defects of the lung, foregut, trachea and oesophagus as seen in Shh, Gli2 and Gli3 mutants (20) (21) (22) (23) . Moreover, Foxf1 heterozygous mice are described to exhibit diminished expression of Gli3, Bmi1 (24) , Igf2 (17), Hnf3ß and Pdgfrα (25) , known target genes of Hh signaling (3). Our own group has reported on the significant Foxf1 overexpression in RMS of Ptch1-haploinsufficient mice that show a constitutively activated Hh pathway (26) . Altogether these studies suggest that Foxf1 is a putative target gene of Hh signaling.
To substantiate this hypothesis we investigated whether Foxf1 is overexpressed in Ptch1-associated tumors other than RMS and examined its expression levels in BCC and MB by means of semi-quantitative RT-PCR and in situ hybridization. Additionally, we tested whether the expression level of Foxf1 is elevated in Ptch1 null embryos, in which Hh signaling is aberrantly active. Since Foxf1 haploinsufficiency has been demonstrated to diminish the expression of Bmi1 and Notch2 (27) and both genes have previously been found to be overexpressed in BCC and MB (28-32), we furthermore analyzed whether up-regulation of Foxf1 in Ptch1-associated tumors consequently results in an increased expression of these genes. In the current study we demonstrated that Foxf1 and Gli1 are concomitantly overexpressed in Ptch1-associated tumors and Ptch1 null embryos thus suggesting that Foxf1 might be a target gene of the Hh signaling pathway. We furthermore showed for the first time that Bmi1 and Notch2 are upregulated in RMS in comparison to normal skeletal muscle. embryos from crosses between Ptch1 neo67/+ mice were isolated and genotyped as previously described (4) . Two types of BCC of irradiated heterozygous Ptch1 neo67/+ mice that are known to be positive or negative for smooth muscle actin, respectively, were kindly provided by Dr M. Mancuso (33) . Nonneoplastic tissue from skeletal muscle, cerebella and skin of the respective mouse strains as well as a variety of different tissue types (liver, kidney, spleen, lung, heart muscle and cerebral cortex) from wild-type mice, were harvested and immediately stored at -80˚C.
Materials and methods

Animals
Isolation of RNA. Total RNA was extracted from tumors and normal tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA was depleted from DNA and subsequently purified using the RNase free DNase set and RNeasy Mini Kit from Qiagen (Hilden, Germany) according to the manufacturer's protocol. The concentration of RNA was measured by photometry (BioPhotometer, Eppendorf, Hamburg, Germany) and RNA stored at -80˚C.
Semi-quantitative reverse transcription-PCR.
Reverse transcription of total RNA was performed using random hexamers (Roche Diagnostics, Penzberg, Germany) and SuperScriptII reverse transcriptase (Invitrogen). PCR amplifications of the murine genes ß-actin, Foxf1, Gli1, Bmi1 and Notch2 were carried out with 50 ng of cDNA using the forward and reverse primers as given in Table I . PCR reactions were performed in a 20 μl final reaction mixture for 28-32 cycles consisting of 30 sec denaturation at 95˚C, hybridization of primers for 30 sec at 58˚C and extension for 1 min at 72˚C. The individual cycle number for each gene was defined by predetermining the linear range of the PCR. Amplification of ß-actin was used as a reference standard to control the amount of sample RNA.
In situ hybridization. Digoxigenin (DIG)-labeled RNA probes for Gli1 and Foxf1 were prepared from RT-PCR amplified products (primer sequences upon request) by standard RNA synthesis reactions with T7-or T3-RNA Polymerase (Promega, Mannheim, Germany) using the DIG-RNA labeling Mix (Roche Diagnostics). Labeling yield was validated by means of dot blot using Anti-Digoxigenin-AP Fab fragments (Roche Diagnostics). RNA expression analysis was performed on 5 μm thick paraffin-embedded sections of above mentioned RMS specimen that were rinsed in xylene, hydrated in a graded ethanol series and microwaved at 600 W for 30 min. Sections were treated with 0.3% Triton X-100 for 15 min and with proteinase K at 37˚C for 10 min followed by incubation with hybridization buffer (40% formamide, 10% dextran sulphate, 1X Denhardt's solution, 4X SSC, 250 μg/ml yeast total RNA) at 55˚C for 30 min. Then 10 μg salmon sperm DNA were denatured at 95˚C for 10 min, added to 1 μg labeled RNA probe in 100 μl hybridization buffer and heated for 2 min at 70˚C. Sections were incubated at 55˚C overnight in a humidified chamber and then rinsed with 2X SSC/1% SDS at room temperature for 5 min. This was followed by rinsing at 60˚C for 20 min with 0.2X SSC/1% SDS and at room temperature for 10 min with 100 mM Tris HCl and 150 mM NaCl at pH 7.5. Blocking with 4% BSA in 100 mM Tris HCl and 150 mM NaCl was performed at 37˚C for 30 min and sections were then incubated with anti-DIG-Fab-AP (1:500) at 37˚C in a humidified chamber for 2 h. Subsequently, sections were rinsed with 100 mM Tris HCl and 150 mM NaCl at pH 7.5. Sections were buffered at pH 9.5 with 100 mM Tris-HCl, 100 mM NaCl and 50 mM MgCl 2 . For color detection nitro-blue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate in 100 mM Tris-HCl, 100 mM NaCl and 50 mM MgCl 2 was used as recommended by the supplier (Roche Diagnostics). Staining was stopped by incubation with 10 mM Tris-HCl and 1 mM EDTA at pH 8.1 and sections were rinsed with distilled water and stained with hematoxylin for 1 min.
Immunohistochemistry. For immunohistochemical analyses 3 μm thick paraffin sections of RMS and MB were mounted on organo-silane coated slides (DakoCytomation, Hamburg, Germany). After deparaffination and rehydration antigen retrieval was accomplished by microwaving the tissue sections in 0.01 M citrate buffer at 700 W for 15 min. Primary antibodies for Myogenin (DakoCytomation) and Nestin (BD Biosciences, San Jose, CA, USA) were diluted 1:50 and 1:1000 in dilution buffer (DakoCytomation), respectively. For detection of primary antibodies the Animal Research Kit ARK™ (DakoCytomation) was used according to the manufacturer's protocol. Cryosections of BCC were fixed with ice-cold aceton prior to staining with an antibody for muscle actin (DakoCytomation) at a dilution of 1:1000 and detection with ARK™ (DakoCytomation).
Results
Previous studies have demonstrated that haploinsufficiency of Foxf1 results in similar developmental defects of the lung, gut and brain as inactivation of Hh signaling components such as Shh, Gli2 and Gli3 (14, 22) , leading to the assumption that Foxf1 is a putative target gene of this signaling cascade. In order to confirm this hypothesis, we first set out to study the expression pattern of Foxf1 and Gli1, the latter being an indicator of activated Hh signaling (9) , in a variety of nonneoplastic adult tissue types of the mouse. Furthermore, two potential target genes of Foxf1, namely Bmi1 and Notch2, were studied. We detected a high level of Foxf1 and correspondingly of Gli1 in lung and cerebral cortex tissue by means of semi-quantitative RT-PCR (Fig. 1) . In kidney tissue we found an exceptionally high expression level of Gli1. Expression of these two genes as well as of the Bmi1 and Notch2 gene was also found in the other adult tissue types tested. However, no significant trend towards an especially high expression level of Bmi1 or Notch2 was found in any of the examined adult non-neoplastic tissue types (Fig. 1) .
We and others have previously shown that Foxf1 is highly expressed in RMS of human (34) and murine origin (26) . To test whether Foxf1 overexpression is rather associated with Hh signaling than with this specific tumor type, we aimed to determine the expression level of Foxf1 and Gli1 on RMS, MB and BCC of Ptch1 neo67/+ mice. To achieve this, we used tumors of Ptch1 neo67/+ mice maintained on an irradiated (BCC) and non-irradiated CD1 (RMS) or C57-BL6 (MB) background and validated their identity by immunohistochemical stainings. Myogenin, nestin and muscle actin, markers known to label RMS, MB and subtypes of BCC were analyzed, respectively (33, (35) (36) (37) . We detected a strong staining for the respective markers in the tumors under investigation thus substantiating their identity (data not shown). By analyzing these tumors using semi-quantitative RT-PCR, we confirmed an elevated transcription level of Foxf1 in RMS in relation to the one in skeletal muscle, which is in line with our earlier data obtained by microarray and Northern blot analysis (26) . Furthermore, we found an overexpression of Foxf1 in BCC and MB in comparison to non-neoplastic skin and cerebellar tissue, respectively. In parallel to the high Foxf1 expression, we detected an increased expression of Gli1 in all three Ptch1-associated tumors compared to the respective non-neoplastic tissues (Fig. 2) , which has already been described by others (4) and corresponds to its role as a marker of activated Hh signaling. Since Foxf1 haploinsufficiency has been demonstrated to diminish the expression of Bmi1 and Notch2 on the transcriptional level (27), we additionally tested whether an up-regulation of Foxf1 in Ptch1-associated tumors would consequently result in an increased expression of these two genes. Our semi-quantitative RT-PCR detected an upregulation of Bmi1 and Notch2 in RMS, MB and BCC in comparison to the respective normal tissues (Fig. 2) .
In order to ascertain whether Foxf1 might be transcriptionally regulated by a constitutively activated Hh signaling pathway, we analyzed Foxf1 expression in Ptch1 neo67/neo67 embryos by means of semi-quantitative RT-PCR. Homozygous loss of Ptch1 alleles, which leads to aberrantly active Hh signaling, resulted in a strong increase in Foxf1 and Gli1 expression (Fig. 3A) , the latter again was used as a positive control for the induction of the pathway. These results clearly show that the Foxf1 gene is highly expressed in Ptch1-associated tumors and Ptch1 null embryos and might be regulated by Hh signaling. Since our goal was to further explore the nature of Foxf1 and Gli1 overexpression and to localize the expressing cells within the tumor in situ hybridizations were performed exemplary with RMS. Here, we demonstrated that the enhanced expression takes place within the tumor cells thus making a pathologically activated Hh loop in RMS conceivable ( Fig. 3B and 4) .
Discussion
Forkhead box transcription factors play an important role during embryonic development. Amongst other transcription factors, Foxf1 has been linked to the Hh signaling pathway and is thought to be downstream of Shh (22) . The expression pattern of Foxf1 has been investigated previously mainly by means of in situ hybridization and ß-galactosidase staining in Foxf1 haploinsufficient mice and has shown the involvement of this transcription factor in the development of the extraembryonic mesoderm, allantois, lateral mesoderm and endoderm as well as its expression in adult lung, liver, intestine, brain, spleen, heart and urinary bladder (13, 14, 16, 17, 19, 22, 25, 38) . Gli1, however, is a transcriptional activator downstream of Shh that is up-regulated whenever the Hh pathway is activated (9) . In our study we detected a basal expression level of Foxf1 and Gli1 in the adult mouse tissue types tested by means of semi-quantitative RT-PCR confirming our hypothesis of Foxf1 as a potential target gene of the Hh signaling pathway. Notably, we found an exceptionally high expression of Foxf1 along with Gli1 in the cerebrum, lung and kidney. This corresponds with the significant role of Hh signaling during lung and brain development as indicated by previous work (16, 17) However, within the urinary tract the transcription factor Foxf1 had so far only been described in the urinary bladder and urethra of adult rats, but not in the kidney (14) . Our finding that Foxf1 is strongly expressed in the kidney is in line with a study of Hu and colleagues (39) that showed the importance of Gli1 during kidney development. Nevertheless, Foxf1 showed relatively higher expression levels than Gli1 in the spleen and liver. This inconsistency might be due to different levels of Hh signaling activity within the respective tissue types. Collectively, we detected an expression of Foxf1 and Gli1 in the examined adult tissue types indicating the importance of the Hh signaling pathway beyond development as well as Foxf1 as part of this signaling cascade. In addition, we demonstrate ubiquitous expression of Bmi1 and Notch2 in non-neoplastic murine adult kidney, spleen, liver, cardiac muscle, cerebrum and lung as well as in skin, cerebellum and skeletal muscle. We found that the detected expression levels of Bmi1 and Notch2 are in relation to those of Foxf1. This suggests that Bmi1 and Notch2 might be targeted by Hh signaling via activation of Foxf1. It has been described that the Notch signaling pathway plays diverse roles during development and physiological tissue processes as well as in tumor formation (40, 41) , while the Polycomb protein BMI1 regulates stem cell maintenance and is associated with a variety of tumor types (29, 42, 43) . The specific implication of these two genes in the different tissue types and its crosstalk with Hh signaling remains to be further investigated, but the corresponding expression levels of Notch2, Bmi1, Gli1 and Foxf1 point to a common regulatory circuitry (Fig. 3B) .
In contrast, constitutive activation of the Hh signaling pathway, caused for example by mutations in the tumor suppressor gene PTCH1, is known to result in the formation of different tumors, amongst them RMS, BCC and MB (1, 9) . Accordingly, we detected increased expression levels of Gli1 as a marker of Hh signaling activation in these tumors in the Ptch1 neo67/+ mouse model. In a previous study we have already Table I . Gene-specific primers used for semi-quantitative RT-PCR. shown an up-regulation of Foxf1 in RMS of these mice by means of DNA microarrays and Northern blot analysis (26) . Here, we not only confirmed the overexpression of Foxf1 in RMS by means of semi-quantitative RT-PCR, but also found increased levels of Foxf1 in MB and BCC compared to the respective non-neoplastic tissues. High expression levels of GLI1 and FOXF1 have independently been described in human RMS (34, 44) . However, the concomitant expression of Foxf1 and Gli1 in our study rather suggests a common role of Foxf1 in Hh signaling than being a marker for RMS. Notably, a prominent role of forkhead box transcription factors in Hh signaling and associated tumors has already been suggested by others. Sasaki and colleagues were the first to describe that Hh signaling, being essential for the activation of the floor plate in vertebrates, is mediated by the forkhead box transcription factor Foxa2 (45) . During somitogenesis and development of pharyngeal endoderm and head mesenchyme, Shh signals are transduced by Foxd2 and Foxc2 (46, 47) , respectively. On the other hand, MB are known to express high levels of FOXM1 (48) . Similarly, in human BCC, the most prominent tumor type associated with Hh signaling, overexpression of FOXE1 and FOXM1 has been reported to be caused by binding of GLI proteins (49, 50) . However, Teh and colleagues did not find an expression of FOXF1 or FOXA2 in human BCC by screening for the most abundantly expressed forkhead box transcription factors with degenerated PCR primers for the conserved DNA-binding protein motif of forkhead box transcription factors. This suggests that Foxf1 might not be the major forkhead box transcription factor in the transduction process of aberrantly activated Hh signaling during tumorigenesis. Nevertheless, by demonstrating the co-localization of Foxf1 and Gli1 within tumor cells of RMS by in situ hybridization and the concomitant expression of both genes in Ptch1 If Foxf1 is transcriptionally activated through Hh signaling in Ptch1-associated tumors, known target genes of Foxf1 such as Bmi1 and Notch2 (24, 27) should also be up-regulated in these tumors. Previous findings indicating diminished expression levels of Bmi1 and Notch2 as a consequence of Foxf1-haploinsufficiency further strengthen this notion (27) . In proportion to this assumption, we detected a strong expression of Bmi1 and Notch2 in Ptch1-associated RMS, MB and BCC compared to their respective non-neoplastic tissues. This is in line with another study reporting that overexpression of BMI1 was also found to be overexpressed in human BCC (29) . However, the gene NOTCH2 was demonstrated to be overexpressed in MB (31, 32) . Notably, Bmi1 was recently shown to enhance cell proliferation and play a role in tumor cell survival (42, 43) , whereas the Notch signaling pathway plays a significant role in tumorigenesis (41) . In our study we demonstrated that the up-regulation of Bmi1 as well as of Notch2 corresponds to the overexpression patterns of Foxf1 and Gli1, pointing to Bmi1 and Notch2 as target genes of Foxf1 (Fig. 3B) .
Taken together, our data and recent work by others strongly suggest that Foxf1 functions as a target gene of the Hh signaling pathway in Ptch1-associated tumors thereby integrating downstream targets such as Notch2 and Bmi1 into the Hh pathway.
